<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rizzo, Toni</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Di Leo, Angelo</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">CONFIRM Trial Final Analysis of Overall Survival: Fulvestrant 500 versus 250 mg</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2013-02-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">12-13</style></pages><abstract><style  face="normal" font="default" size="100%">The Comparison of Fulvestrant 250 mg and 500 mg in Postmenopausal Women with Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy [CONFIRM] trial compared treatment with 2 doses of fulvestrant (250 vs 500 mg) in postmenopausal women with locally advanced or metastatic estrogen receptor (ER)-positive breast cancer that had recurred or progressed after endocrine therapy. The primary analysis showed that progression-free survival was significantly increased with fulvestrant 500 versus 250 mg [Di Leo A et al. J Clin Oncol 2010]. This article discusses the final analysis of overall survival.</style></abstract><number><style face="normal" font="default" size="100%">20</style></number><volume><style face="normal" font="default" size="100%">12</style></volume></record></records></xml>